

Victor L Serebruany

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5552916/publications.pdf>

Version: 2024-02-01

247
papers

10,351
citations

76326

40
h-index

37204

96
g-index

249
all docs

249
docs citations

249
times ranked

9908
citing authors

#	ARTICLE	IF	CITATIONS
1	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. <i>Circulation</i> , 2011, 123, 2736-2747.	1.6	3,378
2	Variability in platelet responsiveness to clopidogrel among 544 individuals. <i>Journal of the American College of Cardiology</i> , 2005, 45, 246-251.	2.8	713
3	Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events. <i>Circulation</i> , 2003, 108, 939-944.	1.6	306
4	Analysis of Risk of Bleeding Complications After Different Doses of Aspirin in 192,036 Patients Enrolled in 31 Randomized Controlled Trials. <i>American Journal of Cardiology</i> , 2005, 95, 1218-1222.	1.6	304
5	Lack of Adverse Clopidogrel-Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial. <i>Circulation</i> , 2003, 108, 921-924.	1.6	259
6	Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERify Thrombosis risk ASsessment (VERITAS) study. <i>Thrombosis Research</i> , 2007, 119, 277-284.	1.7	198
7	Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. <i>American Heart Journal</i> , 2010, 160, 543-551.	2.7	188
8	Risk of bleeding complications with antiplatelet agents: Meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. <i>American Journal of Hematology</i> , 2004, 75, 40-47.	4.1	159
9	Effects of Reteplase and Alteplase on Platelet Aggregation and Major Receptor Expression During the First 24 Hours of Acute Myocardial Infarction Treatment. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1466-1473.	2.8	157
10	Platelet Inhibition by Sertraline and N-Desmethylsertraline: A Possible Missing Link Between Depression, Coronary Events, and Mortality Benefits of Selective Serotonin Reuptake Inhibitors. <i>Pharmacological Research</i> , 2001, 43, 453-461.	7.1	150
11	Selective Serotonin Reuptake Inhibitors and Increased Bleeding Risk: Are We Missing Something?. <i>American Journal of Medicine</i> , 2006, 119, 113-116.	1.5	146
12	Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel. <i>Archives of Internal Medicine</i> , 2004, 164, 2051.	3.8	142
13	Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. <i>American Heart Journal</i> , 2003, 145, 239-247.	2.7	119
14	Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. <i>American Journal of Cardiology</i> , 1999, 83, 1345-1349.	1.6	118
15	The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2009, 102, 111-119.	3.4	96
16	Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. <i>American Journal of Cardiology</i> , 2002, 90, 893-895.	1.6	86
17	Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2008, 100, 76-82.	3.4	84
18	Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 563-567.	1.0	79

#	ARTICLE	IF	CITATIONS
19	Relationship Between Release of Platelet/Endothelial Biomarkers and Plasma Levels of Sertraline and N-Desmethylsertraline in Acute Coronary Syndrome Patients Receiving SSRI Treatment for Depression. American Journal of Psychiatry, 2005, 162, 1165-1170.	7.2	79
20	Adenosine release: A potential explanation for the benefits of ticagrelor in the PLATElet Inhibition and Clinical Outcomes trial?. American Heart Journal, 2011, 161, 1-4.	2.7	78
21	Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. American Heart Journal, 2000, 139, 320-328.	2.7	77
22	Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. American Heart Journal, 2003, 146, 713-720.	2.7	74
23	Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. American Journal of Cardiology, 2001, 87, 1398-1400.	1.6	69
24	Assessment of Bleeding Events in Clinical Trials—Proposal of a New Classification. American Journal of Cardiology, 2007, 99, 288-290.	1.6	68
25	Timing of Magnesium Therapy Affects Experimental Infarct Size. Circulation, 1995, 92, 2622-2626.	1.6	65
26	Effects of Clopidogrel and Aspirin in Combination Versus Aspirin Alone on Platelet Activation and Major Receptor Expression in Patients After Recent Ischemic Stroke. Stroke, 2005, 36, 2289-2292.	2.0	64
27	Effect of Statins on Platelet PAR-1 Thrombin Receptor in Patients With the Metabolic Syndrome (From) Tj ETQq1 1 0.784314 rgBT /Ov	1.6	64
28	Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of "resistance". American Heart Journal, 2009, 158, 925-932.	2.7	64
29	Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified. Thrombosis and Haemostasis, 2011, 105, 752-759.	3.4	63
30	Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. International Journal of Cardiology, 2000, 75, 15-21.	1.7	61
31	Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis, 2009, 27, 48-56.	2.1	59
32	Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. European Heart Journal, 2010, 31, 227-235.	2.2	59
33	Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. Fundamental and Clinical Pharmacology, 2008, 22, 315-321.	1.9	57
34	Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis, 2001, 159, 239-241.	0.8	54
35	Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. American Heart Journal, 1998, 136, 398-405.	2.7	53
36	Dietary Coenzyme Q10 Supplementation Alters Platelet Size and Inhibits Human Vitronectin (CD51/CD61) Receptor Expression. Journal of Cardiovascular Pharmacology, 1997, 29, 16-22.	1.9	46

#	ARTICLE	IF	CITATIONS
37	Impact of clopidogrel and potent P2Y ₁₂ -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention. <i>Thrombosis and Haemostasis</i> , 2013, 109, 93-101.	3.4	45
38	Increased soluble platelet / endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. <i>European Journal of Heart Failure</i> , 1999, 1, 243-249.	7.1	43
39	Effect of a single dose aspirin on platelets in humans with multiple risk factors for coronary artery disease. <i>European Journal of Pharmacology</i> , 2003, 462, 139-143.	3.5	43
40	Platelet Inhibition with Prasugrel and Increased Cancer Risks: Potential Causes and Implications. <i>American Journal of Medicine</i> , 2009, 122, 407-408.	1.5	41
41	Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 249-253.	1.0	40
42	Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1104-1112.	3.4	40
43	CLOPIDOGREL: THE FUTURE CHOICE FOR PREVENTING PLATELET ACTIVATION DURING CORONARY STENTING?. <i>Pharmacological Research</i> , 1999, 40, 107-111.	7.1	39
44	Magnitude and time course of platelet inhibition with Aggrenox® and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. <i>European Journal of Pharmacology</i> , 2004, 499, 315-324.	3.5	38
45	Dose of Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current and Future Directions. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2006, 11, 170-176.	2.0	37
46	Evaluation of platelets in heart failure: Is platelet activity related to etiology, functional class, or clinical outcomes?. <i>American Heart Journal</i> , 2002, 143, 1068-1075.	2.7	36
47	Are Antiplatelet Effects of Clopidogrel Inhibited by Atorvastatin?. <i>Circulation</i> , 2003, 107, 1568-1569.	1.6	36
48	Prasugrel as a Potential Cancer Promoter: Review of the Unpublished Data. <i>Archives of Internal Medicine</i> , 2010, 170, 1078.	3.8	36
49	Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials “Common patterns in TRITON, RECORD, and PLATO?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 412-414.	3.4	36
50	Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. <i>Thrombosis Research</i> , 2004, 113, 197-204.	1.7	35
51	Uniform platelet activation exists before coronary stent implantation despite aspirin therapy. <i>American Heart Journal</i> , 2001, 142, 611-616.	2.7	34
52	Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. <i>American Journal of Cardiology</i> , 2002, 90, 312-315.	1.6	33
53	Soluble PECAM-1, but Not P-Selectin, Nor Osteonectin Identify Acute Myocardial Infarction in Patients Presenting with Chest Pain. <i>Cardiology</i> , 1999, 91, 50-55.	1.4	32
54	Noncompliance in cardiovascular clinical trials. <i>American Heart Journal</i> , 2005, 150, 882-886.	2.7	31

#	ARTICLE	IF	CITATIONS
55	Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 207-213.	2.1	30
56	Depressed Platelet Status in an Elderly Patient With Hemorrhagic Stroke After Thrombolysis for Acute Myocardial Infarction. <i>Stroke</i> , 1998, 29, 235-238.	2.0	29
57	Effect of Thrombolytic Therapy on Platelet Expression and Plasma Concentration of PECAM-1 (CD31) in Patients With Acute Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 153-158.	2.4	29
58	Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: The Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. <i>American Heart Journal</i> , 2003, 145, 636-642.	2.7	29
59	Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. <i>Thrombosis and Haemostasis</i> , 2012, 107, 338-345.	3.4	29
60	Effects of Magnesium Supplementation in a Porcine Model of Myocardial Ischemia and Reperfusion. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 24, 603-611.	1.9	28
61	Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet) Tj ETQq1 1 0.7843142gBT /Overclock 10 TF	1.9	28
62	Paradoxical Rebound Platelet Activation After Painkillers Cessation: Missing Risk for Vascular Events?. <i>American Journal of Medicine</i> , 2006, 119, 707.e11-707.e16.	1.5	27
63	Prasugrel development â€œ Claims and achievements. <i>Thrombosis and Haemostasis</i> , 2009, 101, 14-22.	3.4	27
64	Viewpoint: â€œUnderutilisation of novel antiplatelet agentsâ€œ myths, generics, and economicsâ€œ. <i>Thrombosis and Haemostasis</i> , 2014, 112, 4-9.	3.4	27
65	Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 217-220.	2.1	26
66	Early Impact of Prescription Omega-3 Fatty Acids on Platelet Biomarkers in Patients with Coronary Artery Disease and Hypertriglyceridemia. <i>Cardiology</i> , 2011, 118, 187-194.	1.4	26
67	Effects of Valsartan and Valeryl 4-Hydroxy Valsartan on Human Platelets: A Possible Additional Mechanism for Clinical Benefits. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 677-684.	1.9	25
68	Escitalopram, but Not Its Major Metabolites, Exhibits Antiplatelet Activity in Humans. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 172-177.	1.4	25
69	The Flow Cytometer Model Markedly Affects Measurement of ex Vivo Whole Blood Platelet-Bound P-Selectin Expression in Patients with Chest Pain. <i>Thrombosis Research</i> , 1999, 96, 51-56.	1.7	24
70	Investigations on 5-HT4 Receptor Expression and Effects of Tegaserod on Human Platelet Aggregation In Vitro. <i>American Journal of Therapeutics</i> , 2010, 17, 543-552.	0.9	24
71	Platelet microRNA for predicting acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 556-564.	2.1	24
72	Soluble Vascular Cell Adhesion Molecule-1 and E-Selectin in Patients With Acute Myocardial Infarction Treated With Thrombolytic Agents 11This study was supported in part by Medtronic, Inc., San Diego, California; and Boehringer Mannheim GmbH, Mannheim, Germany.. <i>American Journal of Cardiology</i> , 1998, 81, 772-775.	1.6	23

#	ARTICLE	IF	CITATIONS
73	Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 15-22.	2.1	23
74	Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. <i>American Heart Journal</i> , 2006, 151, 92-99.	2.7	23
75	The Relations of Major Platelet Receptor Expression during Myocardial Infarction. Monitoring Efficacy of GPIIb/IIIa Inhibitors by Measuring P-selectin?. <i>Thrombosis and Haemostasis</i> , 1999, 81, 314-316.	3.4	22
76	The "Clopidogrel Resistance" Trap. <i>American Journal of Cardiology</i> , 2007, 100, 1044-1046.	1.6	22
77	Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: A randomized, single-blind, 30-day trial. <i>Clinical Therapeutics</i> , 2008, 30, 249-259.	2.5	22
78	The TRITON versus PLATO trials: Differences beyond platelet inhibition. <i>Thrombosis and Haemostasis</i> , 2010, 103, 259-261.	3.4	22
79	The PLATO trial: do you believe in magic?. <i>European Heart Journal</i> , 2010, 31, 764-767.	2.2	22
80	Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1024-1027.	3.4	22
81	Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 9, 229-234.	2.1	21
82	Treatment with selective serotonin reuptake inhibitors for enhancing wound healing. <i>Medical Hypotheses</i> , 2004, 63, 103-109.	1.5	21
83	Gastrointestinal Adverse Events after Dual Antiplatelet Therapy: Clopidogrel Is Safer than Ticagrelor, but Prasugrel Data Are Lacking or Inconclusive. <i>Cardiology</i> , 2013, 126, 35-40.	1.4	21
84	Depressed Plasma Platelet-Activating Factor Acetylhydrolase in Patients Presenting with Acute Myocardial Infarction. <i>Cardiology</i> , 1998, 90, 127-130.	1.4	20
85	Application of platelet function testing to the bedside. <i>Thrombosis and Haemostasis</i> , 2010, 103, 29-33.	3.4	20
86	Drug Discontinuation and Follow-up Rates in Oral Antithrombotic Trials. <i>JAMA Internal Medicine</i> , 2016, 176, 257.	5.1	20
87	Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study. <i>Neuropsychopharmacology</i> , 2007, 32, 2369-2374.	5.4	19
88	The in vitro effects of niacin on platelet biomarkers in human volunteers. <i>Thrombosis and Haemostasis</i> , 2010, 104, 311-317.	3.4	19
89	Comparing Ticagrelor Versus Clopidogrel in Patients With a History of Cerebrovascular Disease. <i>Stroke</i> , 2012, 43, 3409-3410.	2.0	19
90	Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) Trial. <i>American Heart Journal</i> , 2008, 155, 93.e1-93.e7.	2.7	17

#	ARTICLE	IF	CITATIONS
91	Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 411-417.	1.9	17
92	Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?. <i>International Journal of Cardiology</i> , 2016, 215, 372-376.	1.7	17
93	Dipyridamole Decreases Protease-Activated Receptor and Annexin-V Binding on Platelets of Poststroke Patients with Aspirin Nonresponsiveness. <i>Cerebrovascular Diseases</i> , 2006, 21, 98-105.	1.7	16
94	Prasugrel in the Poststroke Cohort of the TRITON Trial: The Clear and Present Danger. <i>Cerebrovascular Diseases</i> , 2008, 26, 93-94.	1.7	16
95	Dyspnea and Reversibility of Antiplatelet Agents: Ticagrelor, Elinogrel, Cangrelor, and Beyond. <i>Cardiology</i> , 2014, 127, 20-24.	1.4	16
96	Prasugrel for arterial coronary thrombosis. <i>Drugs of Today</i> , 2009, 45, 83.	1.1	16
97	Statins Increase Risk of Hemorrhagic Stroke by Inhibition of the PAR-1 Receptor. <i>Cerebrovascular Diseases</i> , 2007, 24, 477-479.	1.7	15
98	The Effects of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Platelet and Inflammatory Biomarkers in Patients with Metabolic Syndrome. <i>Cardiology</i> , 2013, 125, 74-77.	1.4	15
99	Viewpoint: Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2013, 110, 5-10.	3.4	15
100	Mild COVID-19 and Impaired Blood Cell-Endothelial Crosstalk: Considering Long-Term Use of Antithrombotics?. <i>Thrombosis and Haemostasis</i> , 2022, 122, 123-130.	3.4	15
101	Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. <i>American Heart Journal</i> , 2000, 139, 0320-0328.	2.7	15
102	Excess Rates of Nonfatal Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel (Preventing Clinical Events or Chasing) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 compensation for U.S. Patent Application P-17232, "Method for Treating Vascular Diseases With Prasugrel," assigned to Eli Lilly and Company, Indianapolis, Indiana. He has received funding for research studies with clopidogrel. <i>American Journal of Cardiology</i> , 2008, 101, 1364-1366.	1.6	14
103	Distribution of dipyridamole in blood components among post-stroke patients treated with extended release formulation. <i>Thrombosis and Haemostasis</i> , 2009, 102, 538-543.	3.4	14
104	Mortality Benefit in PLATO Cannot Be Explained by Antiplatelet Properties of Ticagrelor. <i>Cardiology</i> , 2010, 117, 231-233.	1.4	14
105	Clinical Utility of the Platelet Function Analyzer (PFA-100) for the Assessment of the Platelet Status in Patients with Congestive Heart Failure (EPCOT trial). <i>Thrombosis Research</i> , 2001, 101, 427-433.	1.7	13
106	Effects of in vitro exposure of alcohol on surface receptor expression of human platelets. <i>Clinical Physiology and Functional Imaging</i> , 2002, 22, 153-156.	1.2	13
107	Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidized low-density lipoproteins in patients after ischemic stroke. <i>Thrombosis and Haemostasis</i> , 2011, 105, 81-87.	3.4	13
108	Disbalance between mortality and non-fatal vascular events in the CHAMPION-PHOENIX trial: The cangrelor efficacy challenge. <i>Thrombosis and Haemostasis</i> , 2014, 111, 3-7.	3.4	13

#	ARTICLE	IF	CITATIONS
109	Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events. <i>International Journal of Cardiology</i> , 2015, 201, 508-512.	1.7	13
110	Validation of Three Platelet Function Tests for Bleeding Risk Stratification During Dual Antiplatelet Therapy Following Coronary Interventions. <i>Clinical Cardiology</i> , 2016, 39, 385-390.	1.8	13
111	Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice. <i>Lipids</i> , 2017, 52, 415-422.	1.7	13
112	NPC 15669, an antiinflammatory leucine derivative, reduces in vitro platelet aggregability in both swine and human plasma. <i>Journal of Thrombosis and Thrombolysis</i> , 1995, 1, 171-178.	2.1	12
113	Adhesion molecules, platelet activation, and cardiovascular risk. <i>American Heart Journal</i> , 2002, 143, 196-198.	2.7	12
114	Antiplatelet Activity During Coadministration of the Selective Serotonin Reuptake Inhibitor Paroxetine and Aspirin in Male Smokers: A Randomized, Placebo-Controlled, Double-blind Trial. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 468-475.	2.0	12
115	Impact of Moderate Blast Exposures on Thrombin Biomarkers Assessed by Calibrated Automated Thrombography in Rats. <i>Journal of Neurotrauma</i> , 2013, 30, 1881-1887.	3.4	12
116	Among antithrombotic agents, prasugrel, but not ticagrelor, is associated with reduced 30day mortality in patients with ST-elevated myocardial infarction. <i>International Journal of Cardiology</i> , 2015, 195, 104-110.	1.7	12
117	Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors. <i>American Journal of Therapeutics</i> , 2018, 25, e202-e212.	0.9	12
118	Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights. <i>Thrombosis and Haemostasis</i> , 2019, 119, 355-357.	3.4	12
119	The FDA Prasugrel Review: Adjudication of Myocardial Infarction Controversy. <i>Cardiology</i> , 2009, 114, 126-129.	1.4	11
120	The In Vitro Effects of Xancor, a Synthetic Astaxanthine Derivative, on Hemostatic Biomarkers in Aspirin-Na ⁺ -ve and Aspirin-Treated Subjects With Multiple Risk Factors for Vascular Disease. <i>American Journal of Therapeutics</i> , 2010, 17, 125-132.	0.9	11
121	Eltrombopag (Promacta), a Thrombopoietin Receptor Agonist for the Treatment of Thrombocytopenia: Current and Future Considerations. <i>American Journal of Therapeutics</i> , 2010, 17, 68-74.	0.9	11
122	Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 33, 22-27.	2.1	11
123	Exploring the reduction in myocardial infarctions in the PLATO trial: Which patients benefited on ticagrelor vs. clopidogrel?. <i>International Journal of Cardiology</i> , 2013, 165, 396-397.	1.7	11
124	Predicting Bleeding Risk by Platelet Function Testing in Patients Undergoing Heart Surgery. <i>Clinical Cardiology</i> , 2015, 38, 679-683.	1.8	11
125	Hemostatic Changes After Dietary Coenzyme Q10 Supplementation in Swine. <i>Journal of Cardiovascular Pharmacology</i> , 1996, 28, 175-181.	1.9	11
126	Antecedent Aspirin Therapy Inhibits Baseline Platelet Activity in Patients Presenting with Acute Myocardial Infarction. <i>Cardiology</i> , 1998, 90, 37-42.	1.4	10

#	ARTICLE	IF	CITATIONS
127	Dyspnoea after AZD6140: safety first?. European Heart Journal, 2006, 27, 1505-1505.	2.2	10
128	The In Vitro Effects of a Novel Vascular Protectant, AGI-1067, on Platelet Aggregation and Major Receptor Expression in Subjects With Multiple Risk Factors for Vascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2006, 11, 191-196.	2.0	10
129	Fluorimetric quantitation of citalopram and escitalopram in plasma: developing an express method to monitor compliance in clinical trials. Clinical Chemistry and Laboratory Medicine, 2007, 45, 513-20.	2.3	10
130	Excess of Solid Cancers After Prasugrel: The Food and Drug Administration Outlook. American Journal of Therapeutics, 2010, , 1.	0.9	10
131	Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: Challenging PLATO mortality rates. International Journal of Cardiology, 2013, 164, 255-258.	1.7	10
132	Clopidogrel Response Variability. American Journal of Therapeutics, 2015, 22, 222-230.	0.9	10
133	Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. Thrombosis and Haemostasis, 2017, 117, 934-939.	3.4	10
134	Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department. Journal of Thrombosis and Thrombolysis, 2001, 11, 155-162.	2.1	9
135	Aggressive antiplatelet strategies: time to reconsider?. European Heart Journal, 2007, 28, 2183-2184.	2.2	9
136	Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. American Heart Journal, 2007, 153, 371-377.	2.7	9
137	Stability validation of paraformaldehyde-fixed samples for the assessment of the platelet PECAM-1, P-selectin, and PAR-1 thrombin receptor by flow cytometry. Journal of Thrombosis and Thrombolysis, 2010, 30, 79-83.	2.1	9
138	Aptamers: the emerging class of future anticoagulation for vascular disease. Expert Review of Cardiovascular Therapy, 2010, 8, 503-507.	1.5	9
139	Cangrelor infusion is associated with an increased risk for bleeding: Meta-analysis of randomized trials. International Journal of Cardiology, 2013, 169, 225-228.	1.7	9
140	Comparison of Three Tests to Distinguish Platelet Reactivity in Patients with Renal Impairment during Dual Antiplatelet Therapy. Nephron, 2016, 132, 191-197.	1.8	9
141	Effects of a novel leumedin NPC 15669 on myocardial stunning and preconditioned infarction size in swine. Journal of Thrombosis and Thrombolysis, 1995, 1, 163-170.	2.1	8
142	Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopenia: present and future perspectives. Expert Opinion on Pharmacotherapy, 2006, 7, 81-89.	1.8	8
143	Whole blood platelet aggregation failed to detect differences between preeclampsia and normal pregnancy. Platelets, 2010, 21, 496-497.	2.3	8
144	Ticagrelor FDA Approval Issues Revisited. Cardiology, 2012, 122, 144-147.	1.4	8

#	ARTICLE	IF	CITATIONS
145	Unclassified Pleomorphic and Spindle Cell Pulmonary Neoplasm with Brain Metastases after Prasugrel. <i>Cardiology</i> , 2013, 124, 85-90.	1.4	8
146	Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial Deaths. <i>American Journal of Medicine</i> , 2017, 130, e245-e246.	1.5	8
147	Worldwide reporting of fatal outcomes after ticagrelor to the US Food and Drug Administration. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 6-9.	3.0	8
148	Failure of Platelet Parameters and Biomarkers to Correlate Platelet Function to Severity and Etiology of Heart Failure in Patients Enrolled in the EPCOT Trial. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 8-15.	0.3	7
149	Effect of eptifibatide for acute coronary syndromes: rapid versus late administration--therapeutic yield on platelets (The EARLY Platelet Substudy). <i>Journal of Thrombosis and Thrombolysis</i> , 2002, 14, 213-219.	2.1	7
150	Hypothesis: Antiplatelet Effects of Selective Serotonin Reuptake Inhibitors Cause Clinical Benefits on Cardiovascular Disease and Increase Risks of Bleeding. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2005, 10, 163-164.	2.0	7
151	NXY-059 for Acute Ischemic Stroke. <i>New England Journal of Medicine</i> , 2006, 354, 2075-2076.	27.0	7
152	Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: Hitting the TARGET in the TENACITY trial?. <i>Thrombosis Research</i> , 2007, 119, 175-181.	1.7	7
153	Antiplatelet "resistance"™ and "non"responders"™: what do these terms <i>really</i> mean?. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 11-18.	1.9	7
154	Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. <i>Cardiovascular Revascularization Medicine</i> , 2011, 12, 94-98.	0.8	7
155	Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 1333-1344.	1.5	7
156	The challenge for predicting bleeding events by assessing platelet reactivity following coronary stenting. <i>International Journal of Cardiology</i> , 2016, 207, 128-131.	1.7	7
157	Should We Use Tegaserod for Irritable Bowel Syndrome?. <i>American Journal of Therapeutics</i> , 2019, 26, e417-e420.	0.9	7
158	Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 210-215.	3.0	7
159	Decreased intraplatelet Ca ²⁺ release and ATP secretion in pediatric nephrotic syndrome. <i>Pediatric Nephrology</i> , 1999, 13, 205-208.	1.7	6
160	Monitoring Platelet Inhibition during Chronic Oral Platelet Glycoprotein IIb/IIIa Blockade: Are We Missing Something?. <i>Thrombosis and Haemostasis</i> , 2000, 83, 356-357.	3.4	6
161	Initial Platelet Activity May Predict Efficacy after Chronic Oral Glycoprotein IIb/IIIa Blockade. <i>Thrombosis Research</i> , 2000, 99, 105-107.	1.7	6
162	Platelet Function and Fibrinolytic Agents: Two Sides of a Coin?. <i>Cardiology</i> , 2001, 95, 55-60.	1.4	6

#	ARTICLE	IF	CITATIONS
163	Rapid platelet inhibition after a single capsule of Aggrenox®: Challenging a conventional full-dose aspirin antiplatelet advantage?. American Journal of Hematology, 2003, 72, 280-281.	4.1	6
164	Comment: Mortality Benefit of No-Load Clopidogrel in COMMIT: Not a Surprise. Journal of Cardiovascular Pharmacology and Therapeutics, 2006, 11, 99-101.	2.0	6
165	Hypokalemia, Cardiac Failure, and Reporting NXY-059 Safety for Acute Stroke. Journal of Cardiovascular Pharmacology and Therapeutics, 2006, 11, 229-231.	2.0	6
166	Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity?. Blood Coagulation and Fibrinolysis, 2007, 18, 91-96.	1.0	6
167	Mortality in the TRACER and ATLAS ACS 2 Trials: Two More Reasons to Audit Vital Records in PLATO. Cardiology, 2012, 123, 11-14.	1.4	6
168	Enhanced platelet reactivity in pediatric depression. Blood Coagulation and Fibrinolysis, 2015, 26, 731-735.	1.0	6
169	Redesigning TRACER trial after TRITON. International Journal of Cardiology, 2015, 197, 44-47.	1.7	6
170	Survival After Solid Cancers in Antithrombotic Trials. American Journal of Cardiology, 2015, 116, 969-972.	1.6	6
171	Plasma fibronectin during myocardial ischemia-reperfusion: Effects of magnesium, diltiazem, and a novel Mac-1 inhibitor. , 1998, 57, 309-314.		5
172	Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 2000, 10, 197-202.	2.1	5
173	Platelets and Thrombolysis: Cooperation or Contrariety?. Cardiology, 2001, 1, 281-290.	0.3	5
174	Spectrofluorimetric assessment of plasma dipyridamole stability: Sample storage for multicenter clinical trials?. Thrombosis Research, 2008, 123, 184-186.	1.7	5
175	Bleeding Risks with Prasugrel in the TRITON Trial: Good News ... Bad News. Cardiology, 2008, 111, 265-267.	1.4	5
176	Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy. Journal of Thrombosis and Thrombolysis, 2009, 27, 438-446.	2.1	5
177	Refuting the Ticagrelor-Aspirin Black Box Warning: And Proposing a Ticagrelor Early-PCI Black Box Warning. International Journal of Cardiology, 2013, 168, 1721-1723.	1.7	5
178	Fatal Sepsis and Systemic Inflammatory Response Syndrome After Off-Label Prasugrel. American Journal of Therapeutics, 2014, 21, e229-e233.	0.9	5
179	Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. Thrombosis and Haemostasis, 2016, 115, 905-910.	3.4	5
180	Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?. American Journal of Therapeutics, 2017, 24, e139-e143.	0.9	5

#	ARTICLE	IF	CITATIONS
181	Verifying Death Reports in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. American Journal of Therapeutics, 2020, 27, e563-e572.	0.9	5
182	Effect of Sulodexide on Circulating Blood Cells in Patients with Mild COVID-19. Journal of Clinical Medicine, 2022, 11, 1995.	2.4	5
183	AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis. Expert Review of Cardiovascular Therapy, 2007, 5, 635-641.	1.5	4
184	Combination Antiplatelet Therapy with Aspirin and Clopidogrel: The Role of Antecedent and Concomitant Doses of Aspirin. Cardiology, 2007, 107, 307-312.	1.4	4
185	Magnitude and time course of platelet inhibition with extended release dipyridamole with or without aspirin in healthy Japanese volunteers. Thrombosis and Haemostasis, 2008, 99, 116-120.	3.4	4
186	Peripheral Vascular Outcomes in the PLATO Trial. American Journal of Therapeutics, 2012, 19, 160-161.	0.9	4
187	Prasugrel. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 253-254.	2.2	4
188	Significant excess of early deaths after prehospital ticagrelor: The ATLANTIC trial challenge. Thrombosis and Haemostasis, 2015, 114, 7-8.	3.4	4
189	The FDA report on vorapaxar in the elderly: A convoluted dilemma. International Journal of Cardiology, 2015, 201, 601-603.	1.7	4
190	Concomitant nitrates enhance clopidogrel response during dual anti-platelet therapy. International Journal of Cardiology, 2016, 203, 877-881.	1.7	4
191	Future of oral antiplatelet therapy: Four challenged hypotheses. Thrombosis and Haemostasis, 2009, 101, 1041-1043.	3.4	3
192	Clopidogrel and Heart Failure Survival. Journal of the American College of Cardiology, 2010, 55, 1308-1309.	2.8	3
193	Extreme All-Cause Mortality in JUPITER Requires Reexamination of Vital Records. Cardiology, 2011, 120, 84-88.	1.4	3
194	Discrepancies in the primary PLATO trial publication and the FDA reviews. International Journal of Cardiology, 2014, 172, 8-10.	1.7	3
195	Vorapaxar for secondary stroke prevention: perspectives and obstacles. Expert Review of Neurotherapeutics, 2015, 15, 1377-1382.	2.8	3
196	Missed bleeding events after ticagrelor in PEGASUS trial: Massive non-compliance, information censoring, or both?. International Journal of Cardiology, 2016, 215, 214-216.	1.7	3
197	Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial. International Journal of Stroke, 2016, 11, 614-617.	5.9	3
198	Filing Sources after Oral P2Y12 Platelet Inhibitors to the Food and Drug Administration Adverse Event Reporting System (FAERS). Cardiology, 2017, 138, 249-253.	1.4	3

#	ARTICLE	IF	CITATIONS
199	CRUSADE Score is Superior to Platelet Function Testing for Prediction of Bleeding in Patients Following Coronary Interventions. <i>EBioMedicine</i> , 2017, 21, 213-217.	6.1	3
200	A Prospective, Randomized, Open-Label, Blinded, Endpoint Study Exploring Platelet Response to Half-Dose Prasugrel and Ticagrelor in Patients with the Acute Coronary Syndrome: HOPE-TAILOR Study. <i>Cardiology</i> , 2017, 138, 201-206.	1.4	3
201	Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and Underreporting. <i>TH Open</i> , 2017, 01, e101-e105.	1.4	3
202	Predicting bleeding risk by simplified PRECISE-DAPT score. <i>Thrombosis Research</i> , 2020, 195, 72-73.	1.7	3
203	Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. <i>Thrombosis and Haemostasis</i> , 2008, 100, 314-8.	3.4	3
204	Prasugrel development - claims and achievements. <i>Thrombosis and Haemostasis</i> , 2009, 101, 14-22.	3.4	3
205	Crossreactivity of Human versus Swine Platelet Surface Antigens Is Similar for Glycoproteins Ib and IIIa, but Not for the Glycoprotein IIb/IIIa Complex. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, 37-41.	2.1	2
206	Selective Serotonin Reuptake Inhibitors: Future Treatment of Vascular Disease?. <i>Cardiology</i> , 2001, 1, 332-340.	0.3	2
207	Relation of platelet activation and myocardial ischemia biomarkers dependent on type of chest pain (abrupt onset versus intermittent) in patients with angina pectoris or non-Q-wave acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002, 90, 310-312.	1.6	2
208	The action of dipyridamole to prevent thrombosis: Practical implications for the treatment and prevention of stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2006, 8, 221-227.	0.9	2
209	Cost-effectiveness of antiplatelet therapy for secondary stroke prevention. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 357-363.	1.4	2
210	Controlled Rosuvastatin Multinational Trial in Heart Failure (The Positive Negative Trial). <i>American Journal of Cardiology</i> , 2008, 101, 1808-1809.	1.6	2
211	Switching Thienopyridines: Hypothetical Versus Real Risks. <i>Journal of the American College of Cardiology</i> , 2008, 51, 775.	2.8	2
212	Lack of outcome benefit and clopidogrel resistance. <i>Thrombosis and Haemostasis</i> , 2010, 103, 415-418.	3.4	2
213	The FDA and PLATO Investigators death lists: Call for a match. <i>International Journal of Clinical Practice</i> , 2021, 75, e14105.	1.7	2
214	De-Escalation of Dual Antiplatelet Regimens in East Asian Patients Undergoing Coronary Intervention. <i>American Journal of Therapeutics</i> , 2020, 27, e611-e612.	0.9	2
215	Survival in Acute Myocardial Infarction Induced by Coronary Ligation: Prognostic Relevance of Certain Hemostatic Factors During the Occlusion Phase. <i>Journal of Thrombosis and Thrombolysis</i> , 1998, 5, 29-35.	2.1	1
216	Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2007, 5, 939-953.	1.5	1

#	ARTICLE	IF	CITATIONS
217	Response to the letter regarding the article “Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: The PLavix Use for Treatment of Diabetes (PLUTO-Diabetes) trial” American Heart Journal, 2008, 155, e49.	2.7	1
218	Plasma clopidogrel metabolites and antiplatelet “resistance” Back to the future. Thrombosis Research, 2008, 122, 725-726.	1.7	1
219	Late Prasugrel Benefit in STEMI Patients?. American Journal of Therapeutics, 2009, 16, 469-470.	0.9	1
220	von Willebrand Factor for Predicting Bleeding and Mortality. Journal of the American College of Cardiology, 2011, 57, 2505-2506.	2.8	1
221	Changes of Ticagrelor Formulary Tiers in the USA: Targeting Private Insurance Providers away from Government-Funded Plans. Cardiology, 2013, 126, 187-190.	1.4	1
222	The FDA review on data quality and conduct in vorapaxar trials: Much better than in PLATO, but still not perfect. International Journal of Cardiology, 2016, 205, 13-16.	1.7	1
223	Aspirin in the elderly “tailored approaches ahead?”. Nature Reviews Cardiology, 2017, 14, 571-572.	13.7	1
224	Potential benefits of prasugrel and ticagrelor in diabetics are not substantiated by the Food and Drug Administration adverse event repository. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 142-143.	3.0	1
225	Meta-analyses of incomplete trial datasets: unreliable and potentially misleading. Heart, 2018, 104, 630-631.	2.9	1
226	Assessing Cancer Signal during Oral Antiplatelet Therapy in the Food and Drug Administration Adverse Event Reporting System: Mission Impossible. TH Open, 2018, 02, e28-e32.	1.4	1
227	Tocilizumab, blood cells, and mild COVID-19: delayed vascular protection by interleukin blockade?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e81-e82.	3.0	1
228	Misreported Cancer Deaths in PLATO Trial. Journal of Clinical Medicine, 2021, 10, 3140.	2.4	1
229	Infections Deaths in the PLATO Trial. TH Open, 2021, 05, e503-e506.	1.4	1
230	Future of oral antiplatelet therapy: four challenged hypotheses. Thrombosis and Haemostasis, 2009, 101, 1041-3.	3.4	1
231	Title is missing!. Blood Coagulation and Fibrinolysis, 2003, 14, 249-253.	1.0	0
232	Comment and Reply on: The dose of aspirin for the prevention of cardiovascular and cerebrovascular events. Current Medical Research and Opinion, 2006, 22, 1669-1670.	1.9	0
233	Telmisartan and Stroke Reduction in the ONTARGET Trial: Benefit beyond Blood Pressure Lowering?. Cerebrovascular Diseases, 2008, 26, 563-564.	1.7	0
234	Effects of Extended-Release Dipyridamole In Vitro on Thrombin Indices Measured by Calibrated Automated Thrombography in Poststroke Survivors. American Journal of Therapeutics, 2012, 19, 407-412.	0.9	0

#	ARTICLE	IF	CITATIONS
235	Mortality after clopidogrel in the non-invasive PLATO cohort and TRILOGY ACS trial: Another mismatched death paradox. International Journal of Cardiology, 2013, 168, 640-642.	1.7	0
236	Effect of Aliskiren and Valsartan Combination Versus Aliskiren Monotherapy on Hemostatic Biomarkers in Hypertensive Diabetics. American Journal of Therapeutics, 2014, 21, 482-490.	0.9	0
237	International central adjudication committee in the PLATO trial: independent body of experts or friendly family picnic?. Expert Review of Cardiovascular Therapy, 2015, 13, 867-869.	1.5	0
238	Ticagrelor and heart surgery controversy: we may have better antiplatelet options. Journal of Thoracic Disease, 2016, 8, 3016-3019.	1.4	0
239	Oral Anticoagulants and Renal Impairment: The Convoluting Dilemma. EBioMedicine, 2016, 8, 21-22.	6.1	0
240	The Reply. American Journal of Medicine, 2017, 130, e357-e358.	1.5	0
241	The Reply. American Journal of Medicine, 2017, 130, e353-e354.	1.5	0
242	Ivabradine for heart failure: regulatory differences in Europe and United States. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 119-121.	3.0	0
243	Less Myocardial Infarction and Stroke Hospitalizations During Middle East Respiratory Syndrome Coronavirus Epidemic in Korea. American Journal of Cardiology, 2020, 132, 176-178.	1.6	0
244	The perils of data sharing, meta-analyses, and estimating cardiovascular risk. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e55-e57.	3.0	0
245	Impact of VKORC1, CYP2C9, and CYP4F2 Polymorphisms on Optimal Warfarin Dose: Does Ethnicity Matters?. American Journal of Therapeutics, 2021, 28, e461-e468.	0.9	0
246	FDA PLATO deaths list challenges aspirin dose–ticagrelor interaction. Reviews in Cardiovascular Medicine, 2021, 22, 553.	1.4	0
247	Current concepts targeting antiplatelet 'resistance'. Kardiologia Polska, 2008, 66, 477.	0.6	0